Education
About Us
Working with TipRanks
Follow Us
Aligos Therapeutics, Inc. (ALGS)
:ALGS
Total Valuation
Aligos Therapeutics has a market cap or net worth of $34.18M. The enterprise value is ―.
Market Cap$34.18M
Enterprise Value―
Share Statistics
Aligos Therapeutics has 5,314,801 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,314,801
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aligos Therapeutics’s return on equity (ROE) is 4.53 and return on invested capital (ROIC) is -172.50%.
Return on Equity (ROE)4.53
Return on Assets (ROA)-1.87
Return on Invested Capital (ROIC)-172.50%
Return on Capital Employed (ROCE)-1.84
Revenue Per Employee56.36K
Profits Per Employee-1.87M
Employee Count70
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aligos Therapeutics is -1.90. Aligos Therapeutics’s PEG ratio is <0.01.
PE Ratio-1.90
PS Ratio0.00
PB Ratio-2.47
Price to Fair Value-8.61
Price to FCF-0.86
Price to Operating Cash Flow-0.89
PEG Ratio<0.01
Income Statement
In the last 12 months, Aligos Therapeutics had revenue of 3.94M and earned -131.21M in profits. Earnings per share was -20.94.
Revenue3.94M
Gross Profit3.94M
Operating Income-89.15M
Pretax Income-130.88M
Net Income-131.21M
EBITDA-89.15M
Earnings Per Share (EPS)-20.94
Cash Flow
In the last 12 months, operating cash flow was -80.74M and capital expenditures -130.00K, giving a free cash flow of -80.87M billion.
Operating Cash Flow-80.74M
Free Cash Flow-80.87M
Free Cash Flow per Share-15.22
Dividends & Yields
Aligos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.71
52-Week Price Change-63.51%
50-Day Moving Average6.50
200-Day Moving Average16.12
Relative Strength Index (RSI)46.34
Average Volume (3m)152.08K
Important Dates
Aligos Therapeutics upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Aligos Therapeutics as a current ratio of 2.86, with Debt / Equity ratio of -28.91%
Current Ratio2.86
Quick Ratio2.86
Debt to Market Cap0.03
Net Debt to EBITDA0.32
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aligos Therapeutics has paid 331.00K in taxes.
Income Tax331.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Aligos Therapeutics EV to EBITDA ratio is -2.48, with an EV/FCF ratio of -2.73.
EV to Sales56.01
EV to EBITDA-2.48
EV to Free Cash Flow-2.73
EV to Operating Cash Flow-2.74
Balance Sheet
Aligos Therapeutics has $56.94M in cash and marketable securities with $8.38M in debt, giving a net cash position of -$48.56M billion.
Cash & Marketable Securities$56.94M
Total Debt$8.38M
Net Cash-$48.56M
Net Cash Per Share-$9.14
Tangible Book Value Per Share-$4.62
Margins
Gross margin is 67.45%, with operating margin of -2259.92%, and net profit margin of -3326.01%.
Gross Margin67.45%
Operating Margin-2259.92%
Pretax Margin-3317.62%
Net Profit Margin-3326.01%
EBITDA Margin-2259.92%
EBIT Margin-2259.92%
Analyst Forecast
The average price target for Aligos Therapeutics is $53.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$53.00
Price Target Upside863.64% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-76.29%
EPS Growth Forecast―